Display options
Cite
Zhang K, Lehner LJ, Praeger D, et al. Glucagonoma-induced acute heart failure. Endocrinol Diabetes Metab Case Rep. 2014;2014:140061doi: 10.1530/EDM-14-0061.
Zhang, K., Lehner, L. J., Praeger, D., Baumann, G., Knebel, F., Quinkler, M., & Roepke, T. K. (2014). Glucagonoma-induced acute heart failure. Endocrinology, diabetes & metabolism case reports, 2014140061. https://doi.org/10.1530/EDM-14-0061
Zhang, Kun, et al. "Glucagonoma-induced acute heart failure." Endocrinology, diabetes & metabolism case reports vol. 2014 (2014): 140061. doi: https://doi.org/10.1530/EDM-14-0061
Zhang K, Lehner LJ, Praeger D, Baumann G, Knebel F, Quinkler M, Roepke TK. Glucagonoma-induced acute heart failure. Endocrinol Diabetes Metab Case Rep. 2014;2014:140061. doi: 10.1530/EDM-14-0061. Epub 2014 Nov 01. PMID: 25520848; PMCID: PMC4219276.
Copy Download .nbib Format: NLM
Share it on

Endocrinol Diabetes Metab Case Rep. 2014;2014:140061. doi: 10.1530/EDM-14-0061. Epub 2014 Nov 01.

Glucagonoma-induced acute heart failure.

Endocrinology, diabetes & metabolism case reports

Kun Zhang, Lukas J Lehner, Damaris Praeger, Gert Baumann, Fabian Knebel, Marcus Quinkler, Torsten K Roepke

Affiliations

  1. Department of Cardiology and Angiology, Charité - Universitätsmedizin Berlin , Charitéplatz 1, 10115, Berlin , Germany.
  2. Department of Nephrology, Charité - Universitätsmedizin Berlin , Charitéplatz 1, 10115, Berlin , Germany.
  3. Department of Endocrinology, Charité - Universitätsmedizin Berlin , Charitéplatz 1, 10115, Berlin , Germany.

PMID: 25520848 PMCID: PMC4219276 DOI: 10.1530/EDM-14-0061

Abstract

UNLABELLED: Neuroendocrine tumours (NETs) represent a broad spectrum of tumours, of which the serotonin-producing carcinoid is the most common and has been shown to cause right ventricular heart failure. However, an association between heart failure and NETs other than carcinoid has not been established so far. In this case report, we describe a 51-year-old patient with a glucagon-producing NET of the pancreas who developed acute heart failure and even cardiogenic shock despite therapy. Heart failure eventually regressed after initialising i.v. treatment with the somatostatin analogue octreotide. Chromogranin A as a tumour marker was shown to be significantly elevated, and it decreased with clinical improvement of the patient. The effects of long-time stimulation of glucagon on the myocardium have not been studied yet; however, sarcoplasmic reticulum calcium leak can be discussed as a possible mechanism for glucagon-induced heart failure.

LEARNING POINTS: Glucagonoma can be a cause for heart failure.i.v. infusion of octreotide can be successfully used to treat glucagonoma-induced acute heart failure.We suggest that cardiac function should be monitored in all NET patients.

References

  1. Annu Rev Physiol. 2014;76:107-27 - PubMed
  2. Circulation. 2007 Dec 11;116(24):2860-5 - PubMed
  3. Circ Res. 2000 Dec 8;87(12):1095-102 - PubMed
  4. Heart. 2004 Jul;90(7):e44 - PubMed
  5. Ann Surg Oncol. 2010 Sep;17(9):2427-43 - PubMed
  6. Circulation. 1972 Mar;45(3):534-42 - PubMed
  7. Ann Oncol. 2008 Oct;19(10):1727-33 - PubMed
  8. Circ Res. 1996 Jan;78(1):102-9 - PubMed
  9. Am J Med Sci. 2001 May;321(5):306-20 - PubMed
  10. Circulation. 1986 Mar;73(3 Pt 2):III4-9 - PubMed

Publication Types